Kornimate/medical-research-clean huggingface dataset:
analgesic effect of perineural fentanyl additive to local anesthetics in femoral nerve block

Conditions: Postoperative Pain

Summary: the purpose of this study is to evaluate the analgesic efficacy of perineural fentanyl combined with local anesthetics in the post operative pain control with continuous femoral nerve block after total knee arthroplasty.


Eligibility criteria:
inclusion criteria: * patients who scheduled to receive knee arthroplasty with general anesthesia * asa physical status 1 or 2 exclusion criteria: * allergy to drug * refuse to the study * asa physical status 3 and 4 * history of drug abuse * cognitive disfunction such as dementia * patients who do not adequate for general anesthesia
comparison of mini squat and endurance training in improving quality of life in knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: interventional type of study in which one group of participants will be given mini squats training and other endurance training to improve the quality of life of knee osteoarthritis patients.

interventional type of study in which one group of participants will be given mini squats training and other endurance training to improve the quality of life of knee osteoarthritis patients. 3 sessions per week for 4 weeks along with interferential therapy

Eligibility criteria:
inclusion criteria: * both gender * grade 2-3 oa * no comorbidity of serious type exclusion criteria: * pain greater than 8 on pns * dm * htn * neurological conditions
high-intensity interval training in patients with spinal muscular atrophy

Conditions: Spinal Muscular Atrophy

Summary: patients with spinal muscular atrophy who are wheelchair users often experience lower back - and gluteal pain, reduced sleep quality, constipation and reduced quality of life - symptoms that regular exercise could potentially alleviate. however, only very little research has been done on exercise for patients who are wheelchair users. the aim of this study is to explore the impact of cycle exercise on patients with spinal muscular atrophy.

spinal muscular atrophy (sma) is a neuromuscular disease affecting the motor neurons of the spinal cord that innervate the skeletal muscles, leading to progressive muscle atrophy and weakness. consequently, many patients end up having to use a wheelchair from an early age. besides the impaired motor function, patients with sma can also experience a variety of symptoms associated with their disease, a sedentary lifestyle and physical inactivity such as lower back and leg pain, obstipation, reduced sleep quality and impacted quality of life. training can help alleviate these symptoms in patients with neuromuscular diseases. however, there isn´t any validated way for patients with sma to train as of today. research has shown that high-intensity interval training (hiit) has been well tolerated among patients with sbma, a disease resembling sma with patients tolerating this form for training well. the aim of this study is to investigate:(1) if hiit could be exercise modality in sma patients (2) and to see what positive effects exercise has for their impaired motor function and related challenges. the investigators will test the participants at baseline, which will be followed by a 8-week control period. after the control period the participants will be tested again before the intervention period. during the intervention period the participants will have to train 5 times a week for 10 minutes. after the intervention period, there will be a final test day, where the final results will be compared with those from the baseline.

Eligibility criteria:
inclusion criteria: * spinal muscular atrophy * age: over 15 years exclusion criteria: * competing disorders (as arthritis) or other muscle disorders as well as heart- or lung related issues. * current psychiatric treatment * unable to use the cycle ergometer due to contractures

Keywords: wheelchair cycle exercise
the functional consequences of the ctns-deletion for the trpv1-receptor in cystinosis patients

Conditions: Cystinosis

Summary: cystinosis is a rare autosomal recessive disorder, characterized by the abnormal accumulation of cystine in the lysosomes. cystinosis is mostly caused by mutations in the cystinosin gene (ctns). the major mutation, which is present in almost 50% of the cystinosis patients, is a 57-kb deletion. this deletion removes the first 9 exons and a part of exon 10 of the ctns gene. exon 10 of the ctns gene is a upstream 5' region that encodes for the carkl gene and also for the first two noncoding exons of the transient receptor potential channel, vanilloid subfamily member 1 (trpv1) gene. trpv1 belongs to the transient receptor potential (trp) superfamily of cation channels. trpv1 is primarily expressed in sensory nerves and is activated by heating (\>43°c) and a wide range of chemical stimuli. one of these chemical stimuli is capsaicin, the pungent ingredient in hot chilli peppers. the effect of binding of the exogenous ligand capsaicin with the trpv1 receptor is well known to provoke the release of a number of bioactive substances including calcitonin gene-related peptide (cgrp). these substances, in turn, act on target cells in the surrounding tissue such as mast cells, immune cells and vascular smooth muscle cells. the resulting response is characterized by redness and warmth (secondary to vasodilatation), swelling (secondary to plasma extravasation) and allodynia (i.e. hypersensitivity to heat and touch secondary to alterations in the excitability of primary sensory neurons). the present study wants to test the following hypotheses: (i) the dbf response to topical applied capsaicin is decreased in cystinosis patients, compared to matched control subjects. (ii) the skin sensitivity response after topical applied capsaicin is decreased in cystinosis patients, compared to matched control subjects. (iii) the temperature sensitivity is decreased in cystinosis patients, compared to matched control subjects.


Eligibility criteria:
inclusion criteria: * only healthy controls: subject is in good health, based on medical history and physical examination * white (caucasian) male or female subjects, aged \> or = 8 year. * subject is capable and willing to give informed consent. exclusion criteria: * any abnormality of the skin which may interfere with the study assessments. * excessive hair growth on the volar surface of the forearm. * excessive tanning (any exposure to sunlight or a tanning bed which would cause a sunburn reaction) throughout the study and incapable to cover the forearms for 24 hours prior to the study period. * subject using topical treatments on the forearm. * history of sensitivity to the fruits of capsicum plants (e.g. chilli peppers). * any situation that can compromise the study, including a predictable lack of cooperation from the volunteer. * female subject is pregnant or breastfeeding.
endometrial injury and single embryo transfer

Conditions: Primary Infertility

Summary: endometrial injury increases clinical pregnancy rate in normoresponder patients undergoing long agonist protocol intracytoplasmic sperm injection cycles with single embryo transfer.

endometrial injury means endometrial biopsy on day 3 of menstrual cycle following down regulation in an ivf patient.

Eligibility criteria:
inclusion criteria: * woman age under 35 years * history of primary infertility * normoresponder (antral follicle count 5-10 in one ovary in early follicular phase * having grade i or ii embryos for transfer * agree to undergo endometrial biopsy during the coh cycle. all patients were stimulated with luteal phase long protocol. exclusion criteria: * endocrinopathies (including diabetes mellitus, hyperprolactinemia, cushing's disease, and congenital adrenal hyperplasia), any systemic disease, collagen disorder, hypercholesterolemia, sickle cell anemia, and a history of neoplasm; -high risk for or history of ohss * using any concurrent medication (e.g., insulin-sensitizing drugs, and gnrh antagonists) * patients who did not proceed to follicle retrieval * severe male infertility requiring tesa/tesa * mullerian tract anomalies * a history of endometrial instrumentation or surgery within a month of the study * not agree to undergo endometrial biopsy during the coh cycle.
prospective cohort study of the ability of mri/dti to diagnose prostate cancer

Conditions: Magnetic Resonance Imaging

Summary: the purpose of this study is to examine if investigators can improve diagnosis of prostate cancer by using mri/dti?

this is a prospective cohort study of the ability of mri/dti to diagnose prostate cancer in men undergoing prostate mri. study design: male adults who are scheduled to undergo mri of the prostate, for clinical reasons, will be subjected to additional 10 minutes of image acquisition inside the mri machine. the added mri/dti acquisition does not involve injection of additional contrast material. investigators will compare between ability of the full mp-mri images to diagnose prostate cancer to that of the mri/dti images

Eligibility criteria:
inclusion criteria: 1. men who are scheduled to undergo mri of the prostate at the department of imaging, in beilinson hospital, rabin medical center 2. age 18-90. 3. men who are willing and able to sign an informed consent form. exclusion criteria: 1) men who cannot complete the full acquisition of the mri and the mri/dti image sequences for any reason.

Keywords: dti prostate cancer mri
the combination of gx-188e vaccination and pembrolizumab in patients with hpv 16 and/or 18+ advanced cervical cancer

Conditions: Cervical Cancer

Summary: a multi-center, open-label phase ib-ii trial of the combination of gx-188e vaccination and pembrolizumab in patients with advanced, non-resectable hpv-positive cervical cancer

this is an open-label phase ib-ii trial to evaluate the safety and efficacy of gx-188e (im administration using ichor tds-im device) + pembrolizumab (p) in patients with advanced hpv-16+ or hpv-18+ cervical cancer.

Eligibility criteria:
inclusion criteria: 1. patients must be female and age ≥ 18 years (19 years for korean sites) 2. patients with histologically confirmed advanced or metastatic hpv-positive (hpv-16 or hpv-18) cervical cancer, who have disease progression after treatment with all available therapies for metastatic disease that are known to confer clinical benefit, or are intolerant to treatment, or refuse standard treatment. 3. eastern cooperative oncology group (ecog) performance status of 0-1 4. life expectancy of at least 6 months 5. patients must agree to provide either an archival tumor tissue sample or fresh biopsy sample for baseline biomarker tissue analyses, including staining for pd-l1. if archival tissue is not available and the patient does not have biopsy-accessible tumor lesions, the patient will be excluded. exclusion criteria: 1. patient has disease that is suitable for local therapy administered with curative intent. 2. patient has a known additional malignancy that is progressing or has required active treatment within the past 3 years. 3. patient is expected to require any other form of antineoplastic therapy while on study; including systemic chemotherapy, radiation therapy (except for palliative purposes) biological therapy, or immunotherapy not specified in this protocol. 4. patient has a history of active central nervous system (cns) metastases and/or carcinomatous meningitis. 5. patients have received prior therapy with an anti-pd-1, anti-pd-l1, or anti pd-l2 agent or with an agent directed to another stimulatory or co-inhibitory t-cell receptor (e.g., ctla-4, ox 40, cd137) and was discontinued from that treatment due to a grade 3 or higher immune-related adverse event (irae) 6. patients with active autoimmune disease requiring systemic immunosuppressive treatment within the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed. 7. patients has had an allogeneic solid organ or allogeneic bone marrow transplant

Keywords: keytruda® pembrolizumab gx-188e tds-im device keynote-567
comparative study between (fc-sems) and (pc-sems) in the palliation of dysphagia due to malignant neoplasm of esophagus.

Conditions: Esophageal Neoplasms; Dysphagia

Summary: esophageal cancer is the seventh most common type of cancer in the world, with an estimated global incidence of 604,100 new cases per year. the main symptom of esophageal cancer is dysphagia, associated or not with weight loss. unfortunately, due to asymptomatic presentation in the early stages, more than half of patients are diagnosed in advanced stages of the disease, becoming ineligible for treatment with curative intent. in this sense, chemotherapy and radiotherapy are the pillars of palliative treatment, often regressing the injury and improving symptoms. however, some patients persist with dysphagia. in this scenario, esophageal prostheses are one of the main tools in the palliative treatment of esophageal cancer dysphagia, obtaining rapid and lasting relief of dysphagia. this study aims to compare fully covered (fc-sems) and partially covered (pc-sems) esophageal prostheses in this context, evaluating the number of reinterventions in each group, as well as the occurrence of adverse events. however, it is expected that with the data obtained it is possible to develop clearer and more effective protocols in the palliation of malignant dysphagia of esophageal stenosis.

study design: prospective and randomized study will be conducted. preparation and technical steps of the procedure: the placement of the esophageal prosthesis will be performed under sedation or general anesthesia supervised by the anesthesiologist at the endoscopy service of the cancer institute of the state of são paulo (icesp). the tests will be performed under radioscopic control. the tests will be performed on an outpatient basis, and hospitalization may occur in case of clinical need.

Eligibility criteria:
inclusion criteria: * patients with advanced malignant neoplasm of the esophagus, whether or not undergoing chemotherapy or radiotherapy; * dysphagia score greater than 2 or presence of malignant esophagorespiratory fistula; * indication of palliation of dysphagia through the placement of esophageal prostheses in a multidisciplinary meeting. exclusion criteria: * patients under 18 years; * extraesophageal neoplasms; * lesions with longitudinal extension less than 30 mm; * previous treatment with esophageal prosthesis; * tumors easily transposed to standard endoscope (9.8mm).

Keywords: esophageal neoplasms palliation of dysphagia esophageal stent
statewide implementation of electronic health records

Conditions: Medication Errors

Summary: to determine the effects of electronic health record use on medication error rates in primary care office practices. hypothesis: adoption of electronic health records through this program will reduce medication errors

from the practices committed to implementing ehr in early 2005, we randomly selected 15 adult community-based primary care physicians. we selected 15 similar physicians in practices that were not planning to adopt in that time period. at each of these physicians' practices we documented rates of medication errors for one week prior to the implementation of an ehr using duplicate prescription pads. two months after the implementation in the adopting group, allowing some time for familiarization with the tool, we collected two weeks of data using computer-based information (in the adopting arm) and duplicate prescriptions (in the non-adopting arm).

Eligibility criteria:
inclusion criteria: * all patients of physicians participating in the study exclusion criteria: * any patients who are not part of a panel of a participating physician * any patients who are younger than 18 years of age * any patients who came in for a second visit within each data collection period

Keywords: medication errors adverse drug events electronic health records
determination of factors effecting falls in patients with copd

Conditions: Pulmonary Disease, Chronic Obstructive; Fall; Balance; Distorted

Summary: the aim of this study is to determine the factors affecting falls in patients with copd.

the aim of this study is to determine the factors affecting falls in patients with copd. in accordance with the purposes, at least 100 patients with copd who are 45-80 years old and clinically stable for four weeks will be included. tests and questionnaires will be used in order to determine the severity of disease. lung function test and respiratory muscle strength will be performed. six minute walk test and six minute pegboard and ring test will be performed with an armband that measures energy expenditure for functional exercise capacity for functional exercise capacity. to evaluate posture, the corbin postural assessment scale will be used. hand grip test, periphreal muscle strength test, time up and go test and one minute sit to stand test will be performed. international physical activity questionnaire - short form (ipaq) will be used to determine physical activity level. mini- besttest and activity-specific balance confidence scale were used to determine fall risk. according to the results to be obtained factors affecting falls will be determined in patients with copd. it will guide professional working in this field.

Eligibility criteria:
inclusion criteria for chronic obstructive pulmonary disease group; * being between the ages of 45 and 80, * being literate, * willing to participate in the study, * having copd classified as stage 1-2-3-4 according to the global initiative for chronic obstructive lung disease (gold) system, * being clinically stable for the past 4 weeks. exclusion criteria for chronic obstructive pulmonary disease group; * having a history of lung cancer, sarcoidosis, tuberculosis, and/or lung surgery, * having any neurological, neuromuscular, vestibular, or cardiac disease that could affect the measurements, * receiving long-term oxygen therapy.
choroid in coronary artery disease

Conditions: Choroid Diseases

Summary: purpose: to investigate any relationship between choroid thickness (cth) and coronary artery disease (cad), particularly in its earlier stages before clinically evident. design: retrospective, cross-sectional observational study methods: setting: the study was performed in two institutions; patients were recruited in balikesir city hospital. the ophthalmological examinations and coronary angiograms were performed in balikesir city hospital. the analysis of the coronary angiograms including gensini scoring were conducted in bursa education and research hospital. study population: the study group comprised 68 patients with documented cad and 60 healthy control subjects. patients with high myopia, cataracts, retinal vascular disease, retinal surgery, retinal dystrophy, laser photocoagulation, intravitreal anti-vegf treatment, glaucoma, uveitis, retinal disorders, any systemic diseases were excluded from the study groups. observation procedure: refractive examination, corrected visual acuity, intraocular pressure measurements, anterior and posterior segment examinations. following measurements of macular thickness and retinal nerve fiber layer, choroidal thickness of both eyes was assessed by enhanced depth imaging optical coherence tomography.


Eligibility criteria:
inclusion criteria: * normal coronaries at coronary angiography for healthy control group * without any coronary artery disease equivalent diseases such as peripheral artery disease, cerebrovascular disease and stroke for healthy control group * ability to give informed consent for the study * coronary artery disease with stenosis detected in coronary angiogram for coronary artery disease group exclusion criteria: * high myopia (\> 6d) * cataracts * retinal vascular disease * retinal surgery * retinal dystrophy * laser photocoagulation * intravitreal anti-vegf treatment * glaucoma * uveitis * retinal disorders (comprising diabetic macular edema, diabetic/hypertensive retinopathy, vein occlusions, retinal dystrophy, epiretinal membrane, vitreomacular traction, age-related macular degeneration) * any systemic diseases * obesity (body-mass index ≥30 kg/m²)

Keywords: coronary artery disease choroid gensini score optical coherence tomography
to evaluate the safety and pharmacokinetic interaction between hodo-22251 and hodo-22252 in healthy adults

Conditions: Type 2 Diabetes; Dyslipidemias

Summary: the purpose of this study is to evaluate pharmacokinetic interaction and safety of co-administrated 25mg of empagliflozin and 10/10mg ezetimibe/rosuvastatin in steady state in healthy volunteers.

this trial is a phase 1 study to evaluate pharmacokinetic interaction and safety of co-administrated 25mg of empagliflozin and 10/10mg of ezetimibe/rosuvastatin in steady state in healthy volunteers. this is open-label, multiple-dose, two-arm, two-period and fixed-sequence design. in arm a, 18 subjects will be assigned. the subjects take 25mg of empagliflozin for 5days(period 1). after 7days of washout period, the subjects take 10/10mg of ezetimibe/rosuvastatin for 2days and take co-administrated 25mg of empagliflozin and 10/10mg of ezetimibe/rosuvastatin for 5days. in arm b, 38 subjects will be assigned. the subjects take 10/10mg of ezetimibe/rosuvastatin for 7days(period 1). after 14days of washout period, the subjects take 25mg of empagliflozin for 2days and take co-administrated 25mg of empagliflozin and 10/10mg of ezetimibe/rosuvastatin for 5days.

Eligibility criteria:
inclusion criteria: * signed informed consent * age: 19 and over , healthy volunteer * body mass index (bmi): 18.5≤bmi≤29.9 kg/m² exclusion criteria: * incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination or effects of the study drugs will not be normal * clinically relevant findings(e.g. blood pressure, electrocardiogram(ecg); physical and gynecological examination, laboratory examination)